论文部分内容阅读
作者自1992年5月～1997年1月间于50例白血病患者进行非血缘间骨髓移植(BMT),从白血病的危险度和急性GVHD重度来回顾治疗转归,以作提高疗效的参考。根据白血病的危险度分为标危组24例,即急性白血病的初次缓解期,慢粒白血病(CML)的初次缓解期;高危组13例为急性白血病的第二次缓解期,CML的第二次慢性期或移行期;超高危组13例为急性白血病的非缓解期和CML急性转化期,以及难治性贫血以外的骨髓增生异常综合征(MDS)。 根据患者全身状况,将环磷酰胺、阿糖胞苷、马利兰、马法兰及全身照射作不同的组合进行预处理。按GVHD危险度作相应处理,GVHD标危患者采用环孢素(Csp)3mg/kg加氨甲蝶呤(15mgdl;10mgd3、d5)。GVHD高危患者采用CD6单抗TP120从
The authors performed non-bone marrow transplantation (BMT) in 50 patients with leukemia from May 1992 to January 1997. The risk of leukemia and the severity of acute GVHD were used to review the outcomes of the therapy for reference. According to the risk of leukemia, 24 patients were divided into the standard risk group, namely, the initial remission of acute leukemia and the first remission of chronic myelogenous leukemia (CML); 13 patients in the high-risk group were the second remission of acute leukemia, and the second of CML. In the second chronic phase or transitional phase, 13 patients in the ultra high-risk group were non-remission stage of acute leukemia and CML acute transformation stage, and myelodysplastic syndrome (MDS) other than refractory anemia. According to the general condition of the patient, cyclophosphamide, cytarabine, marilean, melphalan and whole body irradiation were pretreated in different combinations. According to GVHD risk, the patients were treated with cyclosporine (Csp) 3mg/kg plus methotrexate (15mgdl; 10mgd3, d5). High-risk patients with GVHD use CD6 monoclonal antibody TP120 from